HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TAP Licenses Prevacid To Novartis For 2009 Switch

This article was originally published in The Tan Sheet

Executive Summary

Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20

You may also be interested in...

TAP buyout leaves Prevacid switch deal intact

Novartis Consumer Health remains "very committed to the Rx-to-OTC switch" of TAP Pharmaceutical Products' proton pump inhibitor Prevacid, the firm told "The Tan Sheet" March 20. Novartis reaffirmed its commitment to switching the hearthburn drug after Japanese drug firm Takeda announced March 19 it obtained a 100 percent stake in TAP when it bought out Abbott's 50 percent share of the joint venture. According to terms of the deal, Takeda will get the rights to Rx Prevacid. TAP will be integrated into Takeda's existing U.S. subsidiaries, which will establish Takeda America Holdings, the Japanese company says. Novartis Consumer Healthcare acquired the trademark and intellectual property rights for OTC Prevacid (lansoprazole) from TAP in December 2005, at which time Novartis announced plans for a switch in 2009 when the drug's patent expires (1"The Tan Sheet" Jan. 2, 2006, p. 6)...

Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal

Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch

Excedrin Migraine Has Untapped Growth Potential, Novartis Says

Novartis sees further promotion of Excedrin Migraine as an "unexploited opportunity" to expand the brand's presence and grow the firm's OTC category

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts